Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Depreciation & Amortization (CF): 2015-2024

Historic Depreciation & Amortization (CF) for Kura Oncology (KURA) over the last 9 years, with Dec 2024 value amounting to $848,000.

  • Kura Oncology's Depreciation & Amortization (CF) fell 21.15% to $164,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $833,000, marking a year-over-year change of. This contributed to the annual value of $848,000 for FY2024, which is 0.12% down from last year.
  • Latest data reveals that Kura Oncology reported Depreciation & Amortization (CF) of $848,000 as of FY2024, which was down 0.12% from $849,000 recorded in FY2023.
  • In the past 5 years, Kura Oncology's Depreciation & Amortization (CF) registered a high of $849,000 during FY2023, and its lowest value of $200,000 during FY2020.
  • Its 3-year average for Depreciation & Amortization (CF) is $832,333, with a median of $848,000 in 2024.
  • In the last 5 years, Kura Oncology's Depreciation & Amortization (CF) spiked by 200.00% in 2021 and then dropped by 0.12% in 2024.
  • Over the past 5 years, Kura Oncology's Depreciation & Amortization (CF) (Yearly) stood at $200,000 in 2020, then skyrocketed by 200.00% to $600,000 in 2021, then surged by 33.33% to $800,000 in 2022, then increased by 6.13% to $849,000 in 2023, then fell by 0.12% to $848,000 in 2024.